2025
Fortetropin® as a Novel Nutraceutical Approach for Sarcopenia.
This white paper presents the results from a preclnical mouse study that evaluated whether daily oral Fortetropin mitigated the loss of mass in adult mice subjected to acute immobilization via hindlimb casting to induce muscle atrophy. Additionally, it presents findings from a clinical study in older adults (~66 years old) who received oral, daily Fortetropin and exhibited an 18% increase in muscle protein fractional synthetic rate compared to the placebo group.
Read Study
2025
Fortetropin® as a Novel Nutraceutical for Facioscapulohumeral Muscular Dystrophy (FSHD)
This white paper presents the results from a preclnical study evaluating Fortetropin in a rodent model of FSHD. Fortetropin treated FSHD mice exhibited significant increases in total muscle mass and improved treadmill performance compared with vehicle treated FSHD controls.
Read Study
2023
Effects of Fortetropin in Cats with Chronic Kidney Disease (CKD).
Fortetropin® supplementation for 12 weeks in cats with CKD was well tolerated, with stable kidney function and no significant proteinuria. About 67% of the cats gained lean muscle mass, averaging +881 g.
Read Study
2022
The impact of fortetropin on safety and tolerability in retired horses.
Fortetropin® was well tolerated in a 2-week trial with retired horses at doses of 24 g and 48 g, with no adverse events reported.
Read Study
2022
Fortetropin supplementation prevents the rise in circulating myostatin but not disuse-induced muscle atrophy in young men with limb immobilization.
This randomized controlled trial showed that Fortetropin® supplementation (19.8 g/day) prevented the rise in circulating myostatin during 2 weeks of single-leg immobilization in young men.
Read Study
2021
The Effects of Fortetropin Supplementation on Body Composition, Strength, and Power in Humans and Mechanism of Action in a Rodent Model
This randomized, placebo-controlled, crossover study in healthy adult dogs found that ingesting either 6 g or 12 g of Fortetropin® did not significantly reduce serum myostatin levels over a 72-hour period. The results suggest that a single dose at these levels may not modulate myostatin in the short term in otherwise healthy dogs, and further research is needed to establish effective dosing.
Read Study
2021
Evaluating the Safety and Tolerability of Fortetropin in Cats.
This safety and tolerability study (PDF) for Fortetropin® in cats found that daily doses between 1 g/day (~200 mg/kg) and 4 g/day (~800 mg/kg) over two weeks were well tolerated, with no serious adverse effects.
Read Study
2020
Evaluation of Fortetropin in geriatric and senior dogs with reduced mobility.
In a 12‑week, randomized, double‑blind, placebo‑controlled study in older dogs with reduced mobility, Fortetropin supplementation resulted in a small but statistically significant improvement in mobility scores (measured by the LOAD questionnaire) at both week 6 and week 12 compared to baseline.
Read Study
2020
Effects of Fortetropin on the Rate of Muscle Protein Synthesis in Older Men and Women: A Randomized, Double-Blinded, Placebo-Controlled Study.
This randomized, double‑blind study in older adults (mean age ~66 years) showed that 21 days of Fortetropin® (19.8 g/day) increased the fractional synthesis rate (FSR) of ~109 muscle proteins by about **18%** compared to placebo.
Read Study
2016
Investigating the Effects of Fertilized Egg Yolk Extract on Myoblast Proliferation and Differentiation.
That DOI (10.1007/s40883-019-00137-y) corresponds to a **cell‑culture study** that looked at fertilized egg-yolk extract (from which Fortetropin is derived) on muscle cells (C2C12 myoblasts). The study found that the extract **promoted proliferation and differentiation** of the myoblasts in a dose-dependent way, suggesting that components of fertilized yolk can encourage muscle growth at a cellular level.
Read Study
2019
Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau leveling osteotomy.
This randomized, double‑blind, placebo-controlled trial in 100 client‑owned dogs recovering from tibial plateau leveling osteotomy found that daily Fortetropin® for 12 weeks prevented a rise in serum myostatin seen in the placebo group.
Read Study
2016
The Effects of Fortetropin Supplementation on Body Composition, Strength, and Power in Humans and Mechanism of Action in a Rodent Model
This randomized controlled trial found that Fortetropin — a proteo‑lipid compound derived from fertilized egg yolk — significantly increased the fractional synthesis rate (FSR) of multiple muscle‑protein ontologies (myofibrillar, mitochondrial, and sarcoplasmic) in older adults compared to placebo.
Read Study
2015
The Impact of Fertilization on the Chicken Egg Yolk Plasma and Granule Proteome.
This study analyzed the protein composition of fertilized versus unfertilized chicken egg yolks 24 hours post-lay and identified 225 proteins. Fertilization altered the abundance of specific proteins, with 9 being up-regulated and 9 down-regulated. Notably, proteins associated with angiogenesis and immune defense, such as pleiotrophin, β-defensin‑11, and mannose-binding lectin, were more abundant in fertilized yolks. These findings suggest that fertilized yolks could serve as a richer source of pro-angiogenic and antimicrobial proteins.
Read Study